(6th Apr 2017, Shanghai, China and San Francisco, US) Frontline today announced Mr. Norman Chen, a venture capitalist and serial entrepreneur in the life sciences and healthcare space to join as Venture Partner. Mr. Chen will be based in the firm’s Silicon Valley office. Mr. Chen has a BS degree in Biology from the Massachusetts Institute of Technology and an MBA from Stanford University. Mr. Chen began his healthcare career at Baxter International, where he was responsible for the kidney dialysis business unit across 13 markets in Asia. In 1995, Mr. Chen founded Asia Renal Care, Ltd. to provide international-standard dialysis services in Asia, and led the company to become the leading independent dialysis group in Asia with over 70 centers in Taiwan, Singapore, the Philippines, Japan, Korea and Malaysia. In 2002, Mr. Chen joined Walden International as Entrepreneur-in-Residence. In 2004, he co-founded DeltaHealth as a provider of international-quality cardiovascular care in China. From 2005-2012, Mr. Chen was a Partner at Fidelity Growth Partners Asia (now renamed as Eight Roads Ventures), where he was responsible for investments in several successful companies in China in the CRO, specialty pharmaceutical, medical device and other healthcare areas including WuxiApptec, NovaMed, Hile, TCT Medical and Adagene. Leon Chen, Founder and Managing Partner of Frontline BioVentures, said, “We’re very pleased to have Norman on board. Norman is a well-recognized investor in the life sciences and healthcare sector. I personally developed and maintained a good relationship with Norman when we were both worked for Fidelity. I believe his joining will be a meaningful plus to our entire team. With Norman’s contribution, we’ll be able to further expand our bandwidth for North America coverage and also share industry resources across the Pacific.”
Frontline BioVentures Announced Norman Chen to Join as Venture Partner